Pratima Chowdary
National Health Service
Research areas: Medicine · Hematology · Hemophilia Treatment and Research · Platelet Disorders and Treatments · Blood transfusion and management
0000-0002-6690-8586
About
I am Professor of Haemophilia and Haemostasis at University College London and Director of the Katharine Dormandy Haemophilia & Thrombosis Centre at the Royal Free Hospital, London. I am currently Chair of the UK Haemophilia Centre Doctors’ Organisation (UKHCDO), a member of the Executive Committee of the European Association for Haemophilia and Allied Disorders (EAHAD), and Co-Director of the UK National Haemophilia Database.
I graduated from Osmania Medical College, Hyderabad, India, and completed my postgraduate training in haematology in Cardiff and London. I have more than 20 years’ experience in the management of inherited and acquired bleeding and thrombotic disorders.
My research focuses on advancing personalised care in haemophilia through improved understanding of disease phenotype, treatment response and long-term outcomes. My interests include biomarkers of joint disease, assessment of bleeding and thrombotic risk, real-world evidence, and the development and implementation of innovative therapies.
I have led and contributed to numerous academic and commercial clinical trials, including studies of extended half-life factor replacement, non-factor therapies and gene therapy. My wider research interests encompass deep phenotyping, rare disorders and precision therapeutics. I have authored or co-authored around 200 peer-reviewed publications and book chapters and contribute to national and international guidelines, working groups, trial steering committees and data safety monitoring boards.
Employment
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (395)
- Concizumab prophylaxis for haemophilia A or B without inhibitors: a plain language summary of the phase 3 explorer8 study Save
- Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study Save
- A revised classification of FVIII concentrates: rationale and novel metrics Save
- New Treatment in Haemophilia: Challenges, Controversies and Uncertainties Save
- Longer-term Survival of UK People with Bleeding Disorders Infected by Human Immunodeficiency Virus and/or Hepatitis C Virus Through Contaminated Blood Transfusions Save
- A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy Save
- 9-year Outcomes of scAAV2/8-LP1-hFIXco Enriched for Full AAV Capsids in Adults With Severe Hemophilia B Save
- A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer Save
- Bringing Gene Therapy Into Real World Clinical Practice Save
- Concizumab Efficacy in Haemophilia A/B in an Intra-patient Comparison vs. Previous Prophylaxis (Phase 3 Explorer8 Study): Post-hoc Sensitivity Analysis Save
- Concizumab Efficacy in Patients With Hemophilia A/B Without Inhibitors from the Phase 3 explorer8 Study: A Post-hoc Sensitivity Analysis for the Intrapatient Comparison of Concizumab With Previous Prophylaxis Save
- Efanesoctocog alfa in patients with severe haemophilia A: European results from XTEND-ed third interim analysis Save
- FRONTIER5 Direct Switch Study: Safety of Initiating Mim8 Prophylaxis Without Washout of Emicizumab Save
- FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Save
- Haemophilic elbow arthropathy treated with therapeutic arthroscopy - A haemophilia tertiary centre experience Save
- In vitro modelling of cancer-associated thrombosis using a microfluidic flow-chamber approach Save
- Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis Save
- Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients With Severe Haemophilia A: European Results From the Third Interim Analysis of XTEND-ed Save
- Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors Save
- Mim8 Prophylaxis in Adults and Adolescents with Hemophilia A: 52-Week Efficacy and Safety Outcomes from the Phase 3 FRONTIER2 Study Save